Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.42 |
| ▸ | PDE8B | O95263 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL115846 | 1.00 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2ALDH1A1FFAR1PDE8B | |
| SCHEMBL144831 | 1.00 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2ALDH1A1FFAR1PDE8B | |
| Hydrochloric Acid SCHEMBL25198974 | 0.98 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2ALDH1A1FFAR1PDE8B | |
| SCHEMBL5781434 | 0.95 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2ALDH1A1FFAR1PDE8B | |
| SCHEMBL1255187 | 0.95 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2ALDH1A1FFAR1PDE8B | |
| SCHEMBL79878 | 0.95 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2ALDH1A1FFAR1PDE8B | |
| SCHEMBL17395340 | 0.94 | PDE8B (0.45) | HSD17B10SMN1; SMN2ALDH1A1PDE8BATM | |
| SCHEMBL5192786 | 0.94 | PDE8B (0.45) | HSD17B10SMN1; SMN2ALDH1A1PDE8BATM | |
| SCHEMBL25415724 | 0.92 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL2462455 | 0.90 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743459-A1 | BICYCLIC AND MONOCYCLIC TRPA1 INHIBITORS | D.E. Shaw Research, LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12617810-B2 | Prodrugs of STAT3 inhibitors | TVARDI OPERATING COMPANY, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4043447-B1 | HALOGENATED TETRACYCLIC TRITERPENE DERIVATIVE, PREPARATION AND APPLICATION THEREOF | SHANGHAI QINGDONG BIOTECHNOLOGY CO LTD (CN) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| US-12492200-B2 | NLRP3 modulators | Birstol Myers-Squibb Company (US) | 2025-12-09 | — | — | US | disclosed |
| CN-115380030-B | N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2025-05-16 | — | — | CN | disclosed |
| WO-2025090774-A1 | CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE | SEAGEN INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025058459-A1 | NOVEL IMIDAZOPYRIDINE-BASED COMPOUND AND COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING, ALLEVIATING, OR TREATING GASTROINTESTINAL INFLAMMATORY DISEASES OR GASTRIC ACID-RELATED DISEASES | (주)휴온스 | 2025-03-20 | — | — | WO | disclosed |
| EP-4511368-A2 | CCR4 ANTAGONISTS | ChemoCentryx, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-1921066-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1606251-A2 | INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR | ChemoCentryx Inc (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1549613-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | Abbott Laboratories (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040171655-A1 | Inhibitors of human tumor-expressed CCXCKR2 | CHEMOCENTRYX, INC. | 2004-09-02 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004058705-A2 | INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR | CHEMOCENTRYX (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
| US-6559140-B2 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBOTT LABORATORIES | 2003-05-06 | — | — | US | disclosed |
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBVIE INC. | 2001-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | HRH4, HRH2, HRH3 | HSD17B10 3071/4885SMN1; SMN2 4433/4885ALDH1A1 1638/4885 |
| US-12617810-B2 | Prodrugs of STAT3 inhibitors | STAT3, JAK2, STAT6 | HSD17B10 525/4885SMN1; SMN2 4308/4885ALDH1A1 436/4885 |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | HSD17B10 3758/4885SMN1; SMN2 1949/4885ALDH1A1 3463/4885 |
| US-12492200-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | HSD17B10 1231/4885SMN1; SMN2 4769/4885ALDH1A1 864/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | HSD17B10 1075/4885SMN1; SMN2 1555/4885ALDH1A1 2330/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | HSD17B10 3758/4885SMN1; SMN2 1949/4885ALDH1A1 3463/4885 |
| US-20040171655-A1 | Inhibitors of human tumor-expressed CCXCKR2 | CCL2, CCR2, CXCR2 | HSD17B10 2715/4885SMN1; SMN2 4742/4885ALDH1A1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.